What is Retatrutide?

Retatrutide is a synthetic peptide composed of 42 amino acids. It is characterized by a triple mechanism of action, as it simultaneously interacts with receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This combined receptor activity distinguishes it from other incretin analogs and is associated with a more complex effect on metabolic processes.

Initially, the molecule was developed with a research focus on type 2 diabetes and obesity. Published clinical data describe a pronounced effect on reducing body weight, improving glycemic control, and favorably influencing some cardiovascular risk indicators.

Observations on Retatrutide

In scientific literature, retatrutide has been considered in relation to its potential influence on several key areas:

• Glucose metabolism control – reductions in HbA1c and indications of improved insulin sensitivity have been described in clinical and experimental settings.
• Body mass reduction – published results report a more pronounced reduction in adipose tissue compared to certain molecules with a dual mechanism.
• Liver indicators – studies have observed changes in lipid profiles and data indicating a significant reduction in hepatic steatosis, with some protocols reporting a reduction of approximately 80%.
• Cardiometabolic markers – improvements in triglyceride levels, arterial pressure, and certain inflammatory indicators have been described.
• Energy balance – scientific models have noted effects associated with increased energy expenditure, stimulated fat oxidation, and appetite suppression.

Administration and Dosage

Scientific literature describes weekly subcutaneous administration. Studies begin with 2 mg and gradually titrate up to 4 mg weekly depending on tolerability and therapeutic effect.

For 5 mg + 2 ml bacteriostatic water:

Concentration = 2.5 mg/ml → 0.4 ml = 1 mg

Example values for 5 mg:

0.1 ml = 0.25 mg

0.2 ml = 0.5 mg

0.3 ml = 0.75 mg

0.4 ml = 1 mg

0.5 ml = 1.25 mg

For 10 mg + 2 ml bacteriostatic water:

Concentration = 5 mg/ml → 0.2 ml = 1 mg

Example values for 10 mg:

0.1 ml = 0.5 mg

0.2 ml = 1 mg

0.3 ml = 1.5 mg

0.4 ml = 2 mg

0.5 ml = 2.5 mg

Scientific Data

Retatrutide has also been studied within the framework of the TRIUMPH-4 clinical trial, phase 3, lasting 68 weeks, conducted in adult participants with overweight or obesity and knee osteoarthritis, without the presence of diabetes. According to published topline results, the following effects were observed:

• Average body weight reduction of up to 28.7% by week 68 in the 12 mg group
• Significant reduction in pain, measured by the WOMAC scale, with a reduction of up to approximately 75.8% from baseline, along with improvement in physical function
• Favorable changes in individual cardiometabolic parameters, including non-HDL cholesterol, triglycerides, hsCRP, as well as a reduction in systolic arterial pressure at the highest dose studied

Possible Side Effects

The most commonly reported adverse reactions in scientific publications are gastrointestinal.

The literature indicates that manifestations are dose-dependent and may include:

• nausea, vomiting, diarrhea or constipation

• reduced appetite

• abdominal discomfort/bloating

Less commonly, potentially more serious risks have been discussed, such as:

• pancreatitis

• gallstone disease, especially with faster weight reduction

• hypoglycemia when combined with other antidiabetic agents

The information is collected and systematized from various scientific sources and studies. It is for educational purposes only and should not be used for diagnosis, treatment, or prevention of diseases.